Lowest-Rated StocksLowest-RatedNYSE:CRL Charles River Laboratories International (CRL) Stock Price, News & Analysis $186.83 -2.39 (-1.26%) (As of 10/8/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Charles River Laboratories International Stock (NYSE:CRL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CRL alerts:Sign Up Key Stats Today's Range$186.68▼$189.5050-Day Range$187.98▼$245.2952-Week Range$161.65▼$275.00Volume718,215 shsAverage Volume597,642 shsMarket Capitalization$9.62 billionP/E Ratio21.98Dividend YieldN/APrice Target$217.33Consensus RatingHold Company OverviewCharles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.Read More… Elon knows the truth, which is why they want him silenced (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Charles River Laboratories International Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks91st Percentile Overall ScoreCRL MarketRank™: Charles River Laboratories International scored higher than 91% of companies evaluated by MarketBeat, and ranked 87th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingCharles River Laboratories International has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 2 buy ratings, 10 hold ratings, and 1 sell rating.Amount of Analyst CoverageCharles River Laboratories International has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Charles River Laboratories International's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth7.29% Earnings GrowthEarnings for Charles River Laboratories International are expected to grow by 7.29% in the coming year, from $10.01 to $10.74 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Charles River Laboratories International is 21.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.65.Price to Earnings Ratio vs. SectorThe P/E ratio of Charles River Laboratories International is 21.98, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 118.32.Price to Earnings Growth RatioCharles River Laboratories International has a PEG Ratio of 4.09. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCharles River Laboratories International has a P/B Ratio of 2.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Charles River Laboratories International's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.67% of the outstanding shares of Charles River Laboratories International have been sold short.Short Interest Ratio / Days to CoverCharles River Laboratories International has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Charles River Laboratories International has recently increased by 29.45%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCharles River Laboratories International does not currently pay a dividend.Dividend GrowthCharles River Laboratories International does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.55 Percentage of Shares Shorted3.67% of the outstanding shares of Charles River Laboratories International have been sold short.Short Interest Ratio / Days to CoverCharles River Laboratories International has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Charles River Laboratories International has recently increased by 29.45%, indicating that investor sentiment is decreasing significantly. News and Social Media1.6 / 5News Sentiment-0.04 News SentimentCharles River Laboratories International has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Charles River Laboratories International this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for CRL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows5 people have added Charles River Laboratories International to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Charles River Laboratories International insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of Charles River Laboratories International is held by insiders.Percentage Held by Institutions98.91% of the stock of Charles River Laboratories International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Charles River Laboratories International's insider trading history. Receive CRL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter. Email Address CRL Stock News HeadlinesCharles River Laboratories International, Inc. (NYSE:CRL) Receives $220.25 Consensus Price Target from BrokeragesOctober 8 at 4:49 AM | americanbankingnews.comEvercore ISI Group Downgrades Charles River Laboratories International (CRL)October 7 at 7:35 PM | msn.comThe Standard Oil of AI?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...October 8, 2024 | Behind the Markets (Ad)Charles River Laboratories International (NYSE:CRL) Stock Rating Lowered by Evercore ISIOctober 7 at 8:40 AM | americanbankingnews.comCharles River Laboratories International (NYSE:CRL) Rating Lowered to Neutral at Bank of AmericaOctober 3, 2024 | americanbankingnews.comCitigroup Downgrades Charles River Laboratories International (NYSE:CRL) to SellOctober 2, 2024 | americanbankingnews.comEvercore ISI Sticks to Their Buy Rating for Charles River Labs (CRL)September 26, 2024 | markets.businessinsider.comCharles River Laboratories International, Inc.'s (NYSE:CRL) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?September 23, 2024 | uk.finance.yahoo.comSee More Headlines CRL Stock Analysis - Frequently Asked Questions How have CRL shares performed this year? Charles River Laboratories International's stock was trading at $236.40 at the beginning of 2024. Since then, CRL shares have decreased by 21.0% and is now trading at $186.83. View the best growth stocks for 2024 here. How were Charles River Laboratories International's earnings last quarter? Charles River Laboratories International, Inc. (NYSE:CRL) posted its earnings results on Wednesday, August, 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.39 by $0.41. The medical research company earned $1.03 billion during the quarter, compared to analysts' expectations of $1.03 billion. Charles River Laboratories International had a trailing twelve-month return on equity of 14.96% and a net margin of 10.83%. Is Charles River Laboratories International buying back stock? Charles River Laboratories International's Board of Directors approved a stock repurchase program on Wednesday, August 7th 2024, which authorizes the company to buy back $1,000,000,000 in shares, according to EventVestor. This means that the company could buy up to 9.6% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's management believes its stock is undervalued. Does Charles River Laboratories International have any subsidiaries? The following companies are subsidiaries of Charles River Laboratories International: Vigene Biosciences Inc., Retrogenix Limited, Cognate BioServices, HemaCare, CiToxLAB, MPI Research, KWS BioTest, and others. Who are Charles River Laboratories International's major shareholders? Top institutional investors of Charles River Laboratories International include Handelsbanken Fonder AB (0.02%), Czech National Bank (0.02%), Czech National Bank (0.02%) and Fulton Bank N.A. (0.01%). Insiders that own company stock include James C Foster, Birgit Girshick, Joseph W Laplume, William D Barbo, Victoria L Creamer, Michael Gunnar Knell, George Massaro, Shannon M Parisotto and Richard F Wallman. View institutional ownership trends. How do I buy shares of Charles River Laboratories International? Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Charles River Laboratories International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Charles River Laboratories International investors own include NVIDIA (NVDA), Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), Salesforce (CRM) and Abbott Laboratories (ABT). Company Calendar Last Earnings8/07/2024Today10/08/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Commercial physical research Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:CRL CUSIP15986410 CIK1100682 Webwww.criver.com Phone(781) 222-6000Fax978-988-5665Employees21,800Year Founded1947Price Target and Rating Average Stock Price Target$217.33 High Stock Price Target$290.00 Low Stock Price Target$175.00 Potential Upside/Downside+16.3%Consensus RatingHold Rating Score (0-4)2.08 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$8.50 Trailing P/E Ratio21.98 Forward P/E Ratio18.66 P/E Growth4.09Net Income$474.62 million Net Margins10.83% Pretax Margin13.25% Return on Equity14.96% Return on Assets6.70% Debt Debt-to-Equity Ratio0.65 Current Ratio1.58 Quick Ratio1.21 Sales & Book Value Annual Sales$4.08 billion Price / Sales2.36 Cash Flow$15.42 per share Price / Cash Flow12.12 Book Value$70.15 per share Price / Book2.66Miscellaneous Outstanding Shares51,510,000Free Float50,840,000Market Cap$9.62 billion OptionableOptionable Beta1.36 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NYSE:CRL) was last updated on 10/8/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Charles River Laboratories International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Charles River Laboratories International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
